Literature DB >> 8167341

Elevated levels of interleukin-1 beta (IL-1 beta) and IL-6 in serum and increased production of IL-1 beta mRNA in lymph nodes of patients with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome.

R K Gherardi1, L Bélec, G Fromont, M Divine, D Malapert, P Gaulard, J D Degos.   

Abstract

To evaluate a possible implication of cytokines in the pathogenesis of polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome, we studied five consecutive patients with this condition, of which four had sclerotic bone lesions and four had multicentric Castleman's disease. Interleukin-1 beta (IL-1 beta) and IL-6 serum levels were determined in these patients (13 serum samples) and in patients with multiple myeloma (5) and Waldenström's macroglobulinemia (5). In situ hybridization of the relevant mRNAs was performed on lymph node specimens of two patients with POEMS syndrome who had Castleman's disease. Elevated serum levels of IL-1 beta (13/13 samples), and IL-6 (7/13 samples) were found in patients with POEMS syndrome. In the other patients, serum IL-1 beta was undetectable or slightly increased and IL-6 was elevated in a single patient with Waldenström's macroglobulinemia. Abundant IL-1 beta mRNA-producing cells were present in interfollicular spaces in the two tested patients, while IL-6 mRNA-producing cells were rare. We conclude that IL-1 beta and IL-6 serum levels may be chronically elevated in patients with POEMS syndrome, and that lymph node may be one site of IL-1 beta overproduction. These results are in keeping with the hypothesis that cytokines mediate systemic manifestations of POEMS syndrome.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8167341

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

Review 1.  Immunological mechanisms in paraneoplastic peripheral neuropathy.

Authors:  J C Antoine
Journal:  Clin Rev Allergy Immunol       Date:  2000-08       Impact factor: 8.667

2.  Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra).

Authors:  Hazem El-Osta; Filip Janku; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2010-05-25       Impact factor: 6.261

3.  Multicentric, Hyaline Vascular Variant of Castleman's Syndrome.

Authors:  V Mukta; Chandragiri Susmitha; Rakhee Kar; Debdatta Basu; A K Das
Journal:  Indian J Hematol Blood Transfus       Date:  2013-07-13       Impact factor: 0.900

Review 4.  Castleman's disease: from basic mechanisms to molecular therapeutics.

Authors:  Hazem E El-Osta; Razelle Kurzrock
Journal:  Oncologist       Date:  2011-03-25

5.  Serial renal biopsy findings in a case of POEMS syndrome with recurrent acute renal failure.

Authors:  Atsuko Y Higashi; Fumiaki Nogaki; Isoroku Kato; Takahiko Ono; Atsushi Fukatsu
Journal:  Clin Exp Nephrol       Date:  2011-10-08       Impact factor: 2.801

6.  Astrocytic alterations in interleukin-6/Soluble interleukin-6 receptor alpha double-transgenic mice.

Authors:  A G Brunello; J Weissenberger; A Kappeler; C Vallan; M Peters; S Rose-John; J Weis
Journal:  Am J Pathol       Date:  2000-11       Impact factor: 4.307

7.  Bone marrow histopathology in POEMS syndrome: a distinctive combination of plasma cell, lymphoid, and myeloid findings in 87 patients.

Authors:  Linda N Dao; Curtis A Hanson; Angela Dispenzieri; William G Morice; Paul J Kurtin; James D Hoyer
Journal:  Blood       Date:  2011-03-08       Impact factor: 22.113

8.  [POEMS syndrome. A rare variant of osteosclerotic multiple myeloma with polyneuropathy, organomegaly, endocrinopathy, M-gradient and skin lesions].

Authors:  M Cohnen; M Uppenkamp; P Meusers; G Brittinger
Journal:  Med Klin (Munich)       Date:  1998-11-15

Review 9.  Paraneoplastic rheumatic syndromes.

Authors:  H J Mitnick
Journal:  Curr Rheumatol Rep       Date:  2000-04       Impact factor: 4.686

10.  Castleman disease.

Authors:  Ibrahiem Saeed-Abdul-Rahman; Ali M Al-Amri
Journal:  Korean J Hematol       Date:  2012-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.